![]() | KIMBALL ELECTRONICS REPORTS Q3 RESULTS WITH DOUBLE-DIGIT SEQUENTIAL MEDICAL SALES GROWTH; COMPANY AFFIRMS GUIDANCE FOR FISCAL 2026 WITH ADJUSTED OPERATING MARGIN EXPECTED AT HIGH END OF RANGE | ||||
“Results for the third quarter were in line with expectations. Sales increased sequentially compared to Q2, driven by strong growth in our medical vertical market, margins remained solid, and cash from operations was positive for the ninth consecutive quarter. We expect Q4 to be a good finish to the year and we are affirming our guidance for fiscal 2026 with adjusted operating margin estimated to be at the high end of the range. As we look forward, the medical CMO continues to be a key part of our strategy and we are making deliberate investments in our capabilities, operating capacity, and commercial focus. When volumes ramp, we expect it to become a meaningful driver of both top line growth and margin expansion. In addition, we continue to focus on inorganic growth as a possible complement to this strategy. We believe this could be a powerful combination for the future of our Company.” Richard D. Phillips Chief Executive Officer | Third Quarter 2026 Highlights •Revenue of $352.9 million, a sequential increase of 3.4% compared to Q2 •Sales in the medical vertical increased 10.2% versus the prior quarter •Operating income of $11.8 million, or 3.3% of net sales, adjusted operating margin of 4.2% •Cash from operations of $14.9 million, the ninth consecutive quarter of positive operating cash generation •Debt of $163.0 million and borrowing capacity of $276.0 million •Cash Conversion Days of 90, an improvement compared to both the prior quarter and Q3 of fiscal 2025 •Invested $4.0 million to repurchase 165,000 shares of common stock •Company affirms guidance for fiscal 2026 with adjusted operating margin expected at the high end of the range | |||||||||||||||||||
Net Sales by Vertical Market For Q3 Fiscal 2026 | ||||||||
Sales in the automotive vertical market decreased 3% compared to the third quarter of fiscal 2025, while sales in medical and industrial each decreased 8%. As a reminder, in the third quarter of fiscal 2025, the Company reported a non-recurring sale of consigned medical inventory totaling $24 million, or 21% of medical sales in that quarter. | ||||||||
![]() | ||||||||
* | Percentage of net sales. | |||||||
| ** | Percentage changes compared to Q3 of fiscal 2025. | |||||||
![]() | Conference Call / Webcast | ||||
Wednesday, May 6, 2026 Live Webcast: investors.kimballelectronics.com/events-and-presentations/events For those unable to participate in the live webcast, the call will be archived at investors.kimballelectronics.com. | |||||
Forward-Looking Statements | ||
Non-GAAP Financial Measures | ||
| About Kimball Electronics, Inc. | ||
![]() | Contact: Andrew D. Regrut Vice President, Investor Relations, Strategic Development, and Treasurer 812.827.4151 Investor.Relations@kimballelectronics.com | |||||||
Three Months Ended | Nine Months Ended | ||||||||||||||||||||||
| March 31, | March 31, | ||||||||||||||||||||||
| (Amounts in Thousands, except EPS) | 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||
| Net Sales | $ | 352,922 | $ | 374,607 | $ | 1,059,805 | $ | 1,106,255 | |||||||||||||||
Operating Income | $ | 11,755 | $ | 11,716 | $ | 36,976 | $ | 29,061 | |||||||||||||||
Adjusted Operating Income (non-GAAP) | $ | 14,781 | $ | 15,706 | $ | 47,623 | $ | 41,629 | |||||||||||||||
| Operating Income % | 3.3 | % | 3.1 | % | 3.5 | % | 2.6 | % | |||||||||||||||
| Adjusted Operating Income (non-GAAP) % | 4.2 | % | 4.2 | % | 4.5 | % | 3.8 | % | |||||||||||||||
| Net Income | $ | 5,719 | $ | 3,817 | $ | 19,442 | $ | 10,403 | |||||||||||||||
Adjusted Net Income (non-GAAP) | $ | 8,033 | $ | 6,837 | $ | 27,208 | $ | 19,718 | |||||||||||||||
Diluted EPS | $ | 0.23 | $ | 0.15 | $ | 0.78 | $ | 0.41 | |||||||||||||||
Adjusted Diluted EPS (non-GAAP) | $ | 0.33 | $ | 0.27 | $ | 1.10 | $ | 0.79 | |||||||||||||||
Three Months Ended | Nine Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| March 31, | March 31, | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| (Amounts in Millions) | 2026 | * | 2025 (2) | * | Percent Change | 2026 | * | 2025 (2) | * | Percent Change | |||||||||||||||||||||||||||||||||||||||||||||||||
Automotive | $ | 160.5 | 46 | % | $ | 165.5 | 44 | % | (3) | % | $ | 487.2 | 46 | % | $ | 533.7 | 48 | % | (9) | % | |||||||||||||||||||||||||||||||||||||||
Medical | 106.1 | 30 | % | 115.2 | 31 | % | (8) | % | 304.0 | 29 | % | 288.9 | 26 | % | 5 | % | |||||||||||||||||||||||||||||||||||||||||||
Industrial excluding AT&M (1) | 86.3 | 24 | % | 93.9 | 25 | % | (8) | % | 268.6 | 25 | % | 281.6 | 26 | % | (5) | % | |||||||||||||||||||||||||||||||||||||||||||
Net Sales excluding AT&M (1) | $ | 352.9 | 100 | % | $ | 374.6 | 100 | % | (6) | % | $ | 1,059.8 | 100 | % | $ | 1,104.2 | 100 | % | (4) | % | |||||||||||||||||||||||||||||||||||||||
AT&M (1) | — | — | % | — | — | % | — | % | — | — | % | 2.1 | — | % | (100) | % | |||||||||||||||||||||||||||||||||||||||||||
| Total Net Sales | $ | 352.9 | 100 | % | $ | 374.6 | 100 | % | (6) | % | $ | 1,059.8 | 100 | % | $ | 1,106.3 | 100 | % | (4) | % | |||||||||||||||||||||||||||||||||||||||
*As a percent of Total Net Sales | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(1)Sales from our Automation, Test, and Measurement business (AT&M), which was divested effective July 31, 2024, were previously included in the industrial vertical | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(2)In the third quarter of fiscal 2025, the Company reported a non-recurring sale of consigned medical inventory totaling $24 million, or 21% of medical sales in that quarter. In addition, beginning in the first quarter of fiscal year 2026, sales to customers related to commercial transportation, previously included in the automotive vertical, are now reflected in the industrial vertical; prior periods have been recast to conform to current period presentation | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
–Automotive includes electronic power steering, body controls, advanced driver-assistance systems, and electronic braking systems | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
–Medical includes sleep therapy and respiratory care, image guided therapy, in vitro diagnostics, drug delivery, AED, and patient monitoring | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
–Industrial includes climate controls, automation controls, public safety, IoT and factory automation, efficient energy, off highway equipment, and commercial transportation | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Condensed Consolidated Statements of Income | |||||||||||||||||||||||
| (Unaudited) | Three Months Ended | ||||||||||||||||||||||
| (Amounts in Thousands, except Per Share Data) | March 31, 2026 | March 31, 2025 | |||||||||||||||||||||
| Net Sales | $ | 352,922 | 100.0 | % | $ | 374,607 | 100.0 | % | |||||||||||||||
| Cost of Sales | 325,107 | 92.1 | % | 347,711 | 92.8 | % | |||||||||||||||||
| Gross Profit | 27,815 | 7.9 | % | 26,896 | 7.2 | % | |||||||||||||||||
| Selling and Administrative Expenses | 15,214 | 4.4 | % | 13,154 | 3.6 | % | |||||||||||||||||
| Restructuring Expense | 850 | 0.2 | % | 2,026 | 0.5 | % | |||||||||||||||||
Asset Impairment | (4) | — | % | — | — | % | |||||||||||||||||
Operating Income | 11,755 | 3.3 | % | 11,716 | 3.1 | % | |||||||||||||||||
| Interest Income | 203 | 0.1 | % | 100 | — | % | |||||||||||||||||
| Interest Expense | (2,072) | (0.6) | % | (2,936) | (0.8) | % | |||||||||||||||||
| Non-Operating Income (Expense), net | (1,099) | (0.3) | % | (1,726) | (0.4) | % | |||||||||||||||||
| Other Income (Expense), net | (2,968) | (0.8) | % | (4,562) | (1.2) | % | |||||||||||||||||
| Income Before Taxes on Income | 8,787 | 2.5 | % | 7,154 | 1.9 | % | |||||||||||||||||
| Provision (Benefit) for Income Taxes | 3,068 | 0.9 | % | 3,337 | 0.9 | % | |||||||||||||||||
Net Income | $ | 5,719 | 1.6 | % | $ | 3,817 | 1.0 | % | |||||||||||||||
| Earnings Per Share of Common Stock: | |||||||||||||||||||||||
| Basic | $ | 0.23 | $ | 0.15 | |||||||||||||||||||
| Diluted | $ | 0.23 | $ | 0.15 | |||||||||||||||||||
| Average Number of Shares Outstanding: | |||||||||||||||||||||||
| Basic | 24,469 | 24,728 | |||||||||||||||||||||
| Diluted | 24,648 | 24,872 | |||||||||||||||||||||
| (Unaudited) | Nine Months Ended | ||||||||||||||||||||||
| (Amounts in Thousands, except Per Share Data) | March 31, 2026 | March 31, 2025 | |||||||||||||||||||||
| Net Sales | $ | 1,059,805 | 100.0 | % | $ | 1,106,255 | 100.0 | % | |||||||||||||||
| Cost of Sales | 975,286 | 92.0 | % | 1,032,332 | 93.3 | % | |||||||||||||||||
| Gross Profit | 84,519 | 8.0 | % | 73,923 | 6.7 | % | |||||||||||||||||
| Selling and Administrative Expenses | 43,166 | 4.1 | % | 37,107 | 3.4 | % | |||||||||||||||||
| Restructuring Expense | 4,083 | 0.4 | % | 9,019 | 0.8 | % | |||||||||||||||||
| Asset Impairment (Gain on Disposal) | 294 | — | % | (1,264) | (0.1) | % | |||||||||||||||||
| Operating Income | 36,976 | 3.5 | % | 29,061 | 2.6 | % | |||||||||||||||||
| Interest Income | 717 | 0.1 | % | 575 | 0.1 | % | |||||||||||||||||
| Interest Expense | (6,520) | (0.6) | % | (11,969) | (1.1) | % | |||||||||||||||||
| Non-Operating Income (Expense), net | (4,403) | (0.5) | % | (4,155) | (0.4) | % | |||||||||||||||||
| Other Income (Expense), net | (10,206) | (1.0) | % | (15,549) | (1.4) | % | |||||||||||||||||
| Income Before Taxes on Income | 26,770 | 2.5 | % | 13,512 | 1.2 | % | |||||||||||||||||
Provision (Benefit) for Income Taxes | 7,328 | 0.7 | % | 3,109 | 0.3 | % | |||||||||||||||||
| Net Income | $ | 19,442 | 1.8 | % | $ | 10,403 | 0.9 | % | |||||||||||||||
| Earnings Per Share of Common Stock: | |||||||||||||||||||||||
| Basic | $ | 0.79 | $ | 0.42 | |||||||||||||||||||
| Diluted | $ | 0.78 | $ | 0.41 | |||||||||||||||||||
| Average Number of Shares Outstanding: | |||||||||||||||||||||||
| Basic | 24,559 | 24,859 | |||||||||||||||||||||
| Diluted | 24,822 | 25,047 | |||||||||||||||||||||
| Condensed Consolidated Statements of Cash Flows | Nine Months Ended | ||||||||||
| (Unaudited) | March 31, | ||||||||||
| (Amounts in Thousands) | 2026 | 2025 | |||||||||
| Net Cash Flow provided by Operating Activities | $ | 29,837 | $ | 105,870 | |||||||
Net Cash Flow used for Investing Activities | (38,090) | (5,160) | |||||||||
Net Cash Flow provided by (used for) Financing Activities | 2,455 | (126,615) | |||||||||
| Effect of Exchange Rate Change on Cash, Cash Equivalents, and Restricted Cash | 540 | 13 | |||||||||
Net Decrease in Cash, Cash Equivalents, and Restricted Cash | (5,258) | (25,892) | |||||||||
| Cash, Cash Equivalents, and Restricted Cash at Beginning of Period | 89,467 | 78,779 | |||||||||
| Cash, Cash Equivalents, and Restricted Cash at End of Period | $ | 84,209 | $ | 52,887 | |||||||
| (Unaudited) | |||||||||||
| Condensed Consolidated Balance Sheets | March 31, 2026 | June 30, 2025 | |||||||||
| (Amounts in Thousands) | |||||||||||
| ASSETS | |||||||||||
| Cash and cash equivalents | $ | 82,462 | $ | 88,781 | |||||||
| Receivables, net | 225,983 | 222,623 | |||||||||
| Contract assets | 75,711 | 71,812 | |||||||||
| Inventories | 273,251 | 273,500 | |||||||||
| Prepaid expenses and other current assets | 43,351 | 36,027 | |||||||||
| Assets held for sale | 6,610 | 6,861 | |||||||||
| Property and Equipment, net | 274,937 | 264,804 | |||||||||
| Goodwill | 6,191 | 6,191 | |||||||||
| Other Intangible Assets, net | 2,039 | 2,427 | |||||||||
Other Assets, net | 113,770 | 104,286 | |||||||||
| Total Assets | $ | 1,104,305 | $ | 1,077,312 | |||||||
LIABILITIES AND SHARE OWNERS’ EQUITY | |||||||||||
| Current portion of long-term debt | $ | 34,682 | $ | 17,400 | |||||||
| Accounts payable | 229,068 | 218,805 | |||||||||
| Advances from customers | 18,590 | 35,867 | |||||||||
| Accrued expenses | 53,178 | 46,489 | |||||||||
| Long-term debt, less current portion | 127,850 | 129,650 | |||||||||
| Other long-term liabilities | 63,295 | 59,217 | |||||||||
| Share Owners’ Equity | 577,642 | 569,884 | |||||||||
| Total Liabilities and Share Owners’ Equity | $ | 1,104,305 | $ | 1,077,312 | |||||||
| Other Financial Metrics | |||||||||||||||||
| (Unaudited) | |||||||||||||||||
| (Amounts in Millions, except CCD) | |||||||||||||||||
| At or For the | |||||||||||||||||
| Three Months Ended | |||||||||||||||||
| March 31, | December 31, | March 31, | |||||||||||||||
| 2026 | 2025 | 2025 | |||||||||||||||
| Depreciation and Amortization | $ | 10.3 | $ | 9.3 | $ | 9.2 | |||||||||||
Cash Conversion Days (CCD) (1) | 90 | 91 | 99 | ||||||||||||||
Open Orders (2) | $ | 602 | $ | 557 | $ | 642 | |||||||||||
Select Financial Results of Automation, Test and Measurement | |||||||||||||||||||||||
| (Unaudited) | |||||||||||||||||||||||
(Amounts in Millions) | |||||||||||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||||||||||
| March 31, | March 31, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| Net Sales | $ | — | $ | — | $ | — | $ | 2.1 | |||||||||||||||
Operating Income (Loss) (1) | $ | — | $ | — | $ | (0.4) | $ | 0.8 | |||||||||||||||
| Reconciliation of Non-GAAP Financial Measures | |||||||||||||||||||||||
| (Unaudited, Amounts in Thousands, except Per Share Data) | |||||||||||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||||||||||
| March 31, | March 31, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| Net Sales Growth (vs. same period in prior year) | (6) | % | (12) | % | (4) | % | (14) | % | |||||||||||||||
| Foreign Currency Exchange Impact | 3 | % | (1) | % | 2 | % | — | % | |||||||||||||||
| Constant Currency Growth | (9) | % | (11) | % | (6) | % | (14) | % | |||||||||||||||
| Selling and Administrative Expenses, as reported | $ | 15,214 | $ | 13,154 | $ | 43,166 | $ | 37,107 | |||||||||||||||
| Stock Compensation Expense | (2,256) | (1,955) | (6,036) | (4,528) | |||||||||||||||||||
| SERP | 76 | (9) | (234) | (285) | |||||||||||||||||||
| Adjusted Selling and Administrative Expenses | $ | 13,034 | $ | 11,190 | $ | 36,896 | $ | 32,294 | |||||||||||||||
Operating Income, as reported | $ | 11,755 | $ | 11,716 | $ | 36,976 | $ | 29,061 | |||||||||||||||
| Stock Compensation Expense | 2,256 | 1,955 | 6,036 | 4,528 | |||||||||||||||||||
| SERP | (76) | 9 | 234 | 285 | |||||||||||||||||||
| Restructuring Expense | 850 | 2,026 | 4,083 | 9,019 | |||||||||||||||||||
| Asset Impairment (Gain on Disposal) | (4) | — | 294 | (1,264) | |||||||||||||||||||
| Adjusted Operating Income | $ | 14,781 | $ | 15,706 | $ | 47,623 | $ | 41,629 | |||||||||||||||
Net Income, as reported | $ | 5,719 | $ | 3,817 | $ | 19,442 | $ | 10,403 | |||||||||||||||
| Stock Compensation Expense, After-Tax | 1,711 | 1,483 | 4,577 | 3,434 | |||||||||||||||||||
| Restructuring Expense, After-Tax | 606 | 1,537 | 2,966 | 6,840 | |||||||||||||||||||
| Asset Impairment (Gain on Disposal), After-Tax | (3) | — | 223 | (959) | |||||||||||||||||||
| Adjusted Net Income | $ | 8,033 | $ | 6,837 | $ | 27,208 | $ | 19,718 | |||||||||||||||
| Diluted Earnings per Share, as reported | $ | 0.23 | $ | 0.15 | $ | 0.78 | $ | 0.41 | |||||||||||||||
| Stock Compensation Expense | 0.07 | 0.06 | 0.19 | 0.14 | |||||||||||||||||||
| Restructuring Expense | 0.03 | 0.06 | 0.12 | 0.27 | |||||||||||||||||||
| Asset Impairment (Gain on Disposal) | — | — | 0.01 | (0.03) | |||||||||||||||||||
| Adjusted Diluted Earnings per Share | $ | 0.33 | $ | 0.27 | $ | 1.10 | $ | 0.79 | |||||||||||||||
| Twelve Months Ended | |||||||||||||||||||||||
| March 31, | |||||||||||||||||||||||
| 2026 | 2025 | ||||||||||||||||||||||
Operating Income, as reported | $ | 53,450 | $ | 48,669 | |||||||||||||||||||
| SERP | 563 | 381 | |||||||||||||||||||||
| Restructuring Expense | 6,054 | 9,783 | |||||||||||||||||||||
| Asset Impairment (Gain on Disposal) | (833) | (788) | |||||||||||||||||||||
| Stock Compensation Expense | 8,027 | 6,278 | |||||||||||||||||||||
Adjusted Operating Income | $ | 67,261 | $ | 64,323 | |||||||||||||||||||
| Tax Effect | 20,770 | 20,174 | |||||||||||||||||||||
| After-tax Adjusted Operating Income | $ | 46,491 | $ | 44,149 | |||||||||||||||||||
Average Invested Capital (1) | $ | 650,994 | $ | 726,208 | |||||||||||||||||||
| ROIC | 7.1 | % | 6.1 | % | |||||||||||||||||||